Chengdu Origen, Vanotech receive US FDA’s IND application clearance of KHN921 to treat hypertrophic cardiomyopathy associated with MYBPC3 mutations: Chengdu, China Saturday, May ...
Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ETUpcoming Data Readout for Cohort 1 of OPGx-BEST1 ...
About Chengdu Origen and Vanotech Chengdu Origen is a clinical-stage gene therapy company focused on developing gene therapy for unmet medical needs and providing meaningful clinical benefits for ...
From revamping security culture to transformation threat hunting operations, 2026’s award-winning projects underscore the ...
Detailed price information for Libra Energy Materials Inc. (LIBR-CN) from The Globe and Mail including charting and trades.
Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S.
The early history of personal computers is stacked with systems such as the Apple II and the Commodore 64 that had the ...
Investigational New Drug application for KHN921 received "study may proceed" from the US FDA. KHN921 is a potential "first-in-class" cardiovascular AAV gene therapy being developed for the treatment o ...
Detailed price information for Core Critical Metals Corp (CCMC-X) from The Globe and Mail including charting and trades.
Paul Keating’s warning that Australia risked becoming a “banana republic” if competitiveness did not improve was made 40 ...
The modern threat to the United States homeland is no longer characterized only by bombs, border infiltration, or spectacular ...
HM Exploration Corp. ("HM Exploration" or "HM" or the "Company") (CSE:HM) (FSE:X5H) is pleased to announce that it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results